New pressures notwithstanding, being a cancer center director is still a dream job, two of the nation’s newest cancer center directors said.
One of the great pleasures of summer is having more time to read.
The Directors: New directors Herbst and Gius chart a future built on AI, collaboration, and rural access
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer.
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception.
When it comes to harnessing artificial intelligence for cancer breakthroughs, Johns Hopkins researchers Alex Szalay, PhD, and Janis Taube, MD, MSc, believe the future begins with data—lots of it.
Researchers at the Salk Institute and Arc Institute and their collaborators unveiled the first body-wide single-cell atlas of two major epigenetic systems: three-dimensional genome folding and DNA methylation—precise patterns of methyl chemical groups tacked onto DNA—measured simultaneously in the same cells.
The United States has a translation problem. Scientific breakthroughs in oncology are accelerating, but clinical trial infrastructure hasn’t kept pace.
